By Mackenzie Tatananni

Moderna has captured investor attention again amid a burst of speculative interest tied to a rare viral outbreak, just days after its stock fell on mixed quarterly earnings.

In the past week, online searches for " Moderna" and "Moderna vaccine" have surged 30% and 80%, respectively, according to Google Trends. These spikes coincide with an explosion of interest in terms such as "hantavirus," "Moderna hantavirus," and "hantavirus vaccine."

Users clearly want to know about the rodent-borne pathogen detected aboard the cruise ship MV Hondius, which is expected to arrive in Spain by Sunday. Hantavirus is relatively uncommon globally and primarily concentrated in parts of Asia and Europe. The Centers for Disease Control and Prevention recorded fewer than 900 cases in the U.S. between 1993 and 2023.

As of Thursday, the World Health Organization had received reports of eight cases tied to the cruise ship outbreak, including three deaths. Five of the eight were confirmed as hantavirus, while the others were suspected cases.

While the contagion risk is low, the flare-up has sparked fears of another pandemic akin to Covid. And beyond its implications for human health, investors also want to know what hantavirus means for one of the world's biggest vaccine manufacturers.

It's easy to get distracted by the hantavirus's mortality rate, which can reach up to 50%. However, it isn't as easily transmissible as Covid. The Andres strain identified on the cruise ship is found primarily in Chile, and the cruise's origination point, Argentina.

This constricted geographical footprint matters for Moderna from a revenue perspective. Evercore ISI noted Thursday that there currently is "no meaningful revenue opportunity," adding that the stock "tends to trade on outbreak headlines well beyond the underlying commercial implications."

Regardless, the explosion of interest has been good for current Moderna shareholders. Since the World Health Organization reported a cluster of hantavirus cases tied to an outbreak on the MV Hondius, shares have gained nearly 16%. The S&P 500 rose 2.6% over the same period.

The stock is only extending its rally. Moderna stock surged nearly 18% to $57.08 on Friday, far outstripping a 0.8% gain for the S&P 500.

Investors are looking to Moderna to deliver another breakthrough, akin to its pivotal role in launching the second authorized Covid-19 vaccine in the U.S. at the height of the pandemic.

The drugmaker has studied hantaviruses for years in collaboration with the U.S. Army Medical Research Institute of Infectious Diseases, and separately is working with the Vaccine Innovation Center at Korea University College of Medicine to explore treatments.

While Moderna hasn't discussed any candidates publicly, the website for its mRNA Access program lists "Hantaan virus" and "Hantaviruses causing Hanta Pulmonary syndrome" as "permitted pathogens." This means mean Moderna shares its mRNA technology and manufacturing capacity with external partners looking to target these viruses.

In a statement Thursday, the company confirmed that it was exploring a hantavirus treatment, styling the efforts as "early-stage and ongoing" and as part of a broader push to address emerging infectious diseases.

Even before latest bout of interest, the stock has been a notably strong performer this year. Including Friday's gains, Moderna has surged 87% in 2026 against an 8% gain for the broader market. Shares have more than doubled over the past 12 months.

Where does Moderna go from here? It's unclear. Even if the company were to produce a treatment -- an effort that seems to be years in the making -- and secure regulatory approval amid heightened scrutiny for its hallmark mRNA technology, the total addressable market for hantavirus is small.

The more pressing stock catalyst will be coming cancer data, as Goldman Sachs analyst Salveen Richter pointed out last week. Moderna is slated to present at the large oncology conference ASCO 2026 at the end of May, following the release of five-year follow-up data for Phase 2 testing of its mRNA-based cancer vaccine in conjunction with Merck's Keytruda immunotherapy.

The vaccine, intismeran autogene, is tailored to patients with solid tumors, particularly high-risk melanoma. Many analysts regard it as the cornerstone of Moderna's oncology pipeline.

Needham analyst Joseph Stringer recently described these programs as Moderna's "major future value drivers." Moving forward, the analyst plans to monitor other data readouts, including the results of two trials evaluating the efficacy of intismeran alone in patients with renal cell carcinoma and as an adjuvant therapy for melanoma.

Write to Mackenzie Tatananni at mackenzie.tatananni@barrons.com

This content was created by Barron's, which is operated by Dow Jones & Co. Barron's is published independently from Dow Jones Newswires and The Wall Street Journal.

(END) Dow Jones Newswires

May 08, 2026 14:44 ET (18:44 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.